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Abstract: Cogan’s syndrome (CS) is a rare disorder characterized by nonsyphilitic interstitial 
keratitis (IK) and audio-vestibular symptoms. CS affects mainly young Caucasian adults, mostly 
during their first three decades of age, and may develop into typical and atypical variants. 
Typical CS manifests primarily with IK and hearing loss, whereas atypical CS usually presents 
with inflammatory ocular manifestations in association with audio-vestibular symptoms but 
mostly different Ménière-like symptoms and, more frequently, with systemic inflammation 
(70%), of which vasculitis is the pathogenic mechanism. CS is considered as an autoimmune- 
or immune-mediated disease supported mainly by the beneficial response to corticosteroids. 
Using well-developed assays, antibodies to inner ear antigens, anti-Hsp70, and antineutrophil 
cytoplasmic antibodies were found to be associated with CS. Corticosteroids represent the first 
line of treatment, and multiple immunosuppressive drugs have been tried with variable degrees 
of success. Tumor necrosis factor-alpha blockers and other biological agents are a recent novel 
therapeutic option in CS. Cochlear implantation is a valuable rescue surgical strategy in cases 
with severe sensorineural hearing loss unresponsive to intensive and/or innovative immunosup-
pressive regimens.
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Introduction
Cogan’s syndrome (CS) is a rare multisystem disease of unknown origin characterized 
by ocular and audio-vestibular symptoms including nonsyphilitic interstitial keratitis 
(IK), conjunctivitis, scleritis, uveitis, retinal vasculitis, hearing loss, vertigo, and tin-
nitus. The association of these symptoms was first described in 1934,1 but CS was 
named after the American ophthalmologist David G Cogan who described a series of 
four cases in 1945.2 The etiology of CS is still debated. An infectious origin seems to be 
possible through a viral involvement that triggers a molecular mimicry mechanism.3,4 
In the recent years, the role of autoimmunity has raised interest in the pathogenesis 
for CS; the demonstration of autoantibodies against corneal, inner ear, and endothelial 
antigens in some patients with CS can further support a significant role for the autoim-
mune nature of this disease.3,4 Other studies suggested a cell-mediated reaction.3 CS 
develops mainly in young Caucasian adults, mostly during their first three decades of 
age, but can also rarely present in childhood or later in life, with no gender-specific 
prevalence.5,6 However, population-based analysis of incidence and prevalence are 
unfeasible due to the rarity of the disease. In this review, the authors initially focus on 
the clinical features of CS, with a brief description of the large  spectrum of  clinical 
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manifestations found in this rare condition; second, the 
authors discuss the pathogenetic basis of the disease, dis-
cussing the more relevant theories available in the literature. 
This review continues with a description of the diagnostic 
and, especially, therapeutic approaches to CS, with special 
attention to the multidisciplinary approach required for these 
patients. At last, a discussion of future options for diagnosis 
and, mainly, treatment of CS is presented.
Clinical features
CS includes a large spectrum of clinical manifestations. 
In 1980, Haynes et al7 defined two types of CS, a typical 
variant and an atypical variant. Typical CS is defined by 1) 
ocular symptoms, classically presenting as nonsyphilitic IK; 
2) audio-vestibular symptoms similar to those of Ménière’s 
disease (recurrent episodes of hearing loss, tinnitus, and 
vertigo often associated with nausea and vomiting); and 3) 
an interval between the onset of ocular and audio-vestibular 
manifestations of <2 years. Atypical CS is characterized by 1) 
different inflammatory ocular manifestations, with or without 
IK; 2) audio-vestibular symptoms (usually progressive hear-
ing loss); and, most important, 3) a delay of >2 years between 
the onset of ocular and audio-vestibular manifestations. In 
many cases, it is difficult to differentiate between the two 
types of CS because some patients do not present IK at the 
onset of the disease or, alternatively, develop this condition 
during the following years. Timing and association between 
symptoms of CS may be extremely variable. Systemic mani-
festations are much more frequent in atypical CS and can 
be used in the differential diagnosis between the two types.
Systemic manifestations are present in ~30%–50% of 
patients in addition to the typical ocular and audio-vestibular 
symptoms.8 Gluth et al9 reported the following systemic 
symptoms in a survey of 60 patients with CS: headache 
(40%), arthralgia (35%), fever (27%), arthritis (23%), and 
myalgia (22%). Vasculitis of small, medium, and large ves-
sels is considered as the underlying pathogenic mechanism 
for systemic presentation of CS,8,10 which may involve the 
cardiovascular, neurological, and gastrointestinal systems.6 
The most typical cardiovascular manifestation of CS is aor-
titis,9,11 leading to kidney and aortic insufficiency, reported 
in ~10% of patients, and congestive heart failure (Figure 
1).3,12 Neurological manifestations may include hemiparesis 
or hemiplegia following cerebral vascular accidents, and 
aphasia, due to transient ischemic events.13,14 Gastrointestinal 
manifestations, such as diarrhea, melena, and abdominal 
pain, have also been reported following a possible involve-
ment of the mesenteric arteritis.15 Inflammatory bowel dis-
ease such as ulcerative colitis and Crohn’s disease are also 
associated with CS.16,17
The most common audio-vestibular manifestations in 
CS are hearing loss, vertigo, tinnitus, ataxia, and oscillopsia. 
These symptoms can appear at any time during the course 
of the disease.9 Hearing loss may be both unilateral and 
bilateral and often presents as sudden sensorineural hearing 
loss with fluctuations or progressive worsening over time. 
Tinnitus, the perception of sound without an accompanying 
external auditory stimulus,18 is often found in patients with 
CS.14 Tinnitus is associated with hearing loss, ototoxic drug 
use, infections, psychological stress, and a range of medical 
conditions that can affect hearing function.18–26 In patients 
with CS, tinnitus appears to be a consequence of peripheral 
auditory deafferentation rather than a direct consequence of 
the pathogenic mechanisms of CS.5 Progression to complete 
bilateral hearing loss has been reported in ~50% of patients 
during the follow-up period, whereas permanent hearing 
loss in one ear was observed in 20% of patients. Abnormal 
vestibular function is found in 90% of patients with CS; at 
least 20% of the patients present spontaneous or gaze-induced 
nystagmus. Rarely, patients present with clinical symptoms of 
vestibulopathy that lasts for days or weeks from the time of 
onset without spontaneous resolution that frequently results 
to hospitalization.9
IK is the most frequent ophthalmologic symptom of 
typical CS, which appears in 80% of cases and is mostly 
bilateral, clinically consisting in an irregular, granular 
 corneal infiltration, which can progress to nummular 
lesions.9 A deep stromal keratitis can occur following vas-
cularization of the cornea particularly affecting the posterior 
part of the cornea, near the limbus. Patient often reported 
eye redness, pain, photophobia, and blurred vision.9 In 
some cases, IK develops later during the course of disease 
and is missed at the initial examination. Other ocular mani-
festations, mainly in patients with atypical CS, are acute 
closure angle glaucoma, retinal vasculitis, conjunctivitis, 
scleritis, papillitis, central vein occlusion, vasculitic optic 
neuropathy, and papilledema. Most of the patients maintain 
normal or near-normal vision, and only few develop some 
degree of visual loss directly attributable to inflammatory 
eye disease.9
Pathogenesis
The pathogenetic basis of CS is still unclear. Infections of 
the upper respiratory tract precede the onset of disease in 
50% of cases, suggesting an infectious origin.6 Chlamydial 
infection in particular has received much attention for its 
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ability to elude host defense mechanisms and cause chronic 
infection. However, a direct link between different Chla-
mydia species and CS has not been proven.27 Moreover, the 
antibodies against the Cogan peptide have been shown to 
cross-react with a structural protein of the Reovirus type III, 
suggesting a viral involvement in the pathogenesis of the 
disease possibly through a molecular mimicry mechanism, 
through which sequence similarities between foreign and 
self-peptides result in the cross-activation of autoreactive 
cells by pathogen-derived peptides.29 This occurs when 
antigenic determinants are shared between exogenous agents 
(viruses, bacteria, food antigens, and others) and normal 
human host–cell components. Molecular mimicry is one of 
the mechanisms whereby autoimmunity can arise.29 In fact, 
Figure 1 The evaluation of the patient’s aortitis and renal disorder.
Notes: MRA (A) and renal histologic (B–D, Periodic acid-Schiff stain) findings in the patient. MRA showed stenosis of the right brachiocephalic artery and proximal 
obstruction in the right subclavian artery (indicated by arrows). Renal histologic findings while proteinuria was worsening included mesangial proliferation with circumferential 
crescent formation (B, ×200) and periglomerular mononuclear cell infiltration (C, ×100). Small renal arteries showed medial thickening, endothelial cell proliferation, and 
thrombosis (D, ×100, indicated by arrows). After treatment with PSL and an immunosuppressant, glomerular and tubular interstitial lesions decreased (E, ×100). However, 
repeated relapses occurred, and a recent specimen showed sclerotic glomeruli (F, ×200). Reproduced from  Sugimoto K, Miyazawa T, Nishi H, Izu A, Enya T, Okada M, 
Takemura T. Childhood Cogan syndrome with aortitis and anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Pediatr Rheumatol Online J. 2014;12:15. 
Copyright © 2014 Sugimoto et al.; licensee BioMed Central Ltd. Creative Commons License available at: https://creativecommons.org/licenses/by/2.0/.65
Abbreviation: MRA, magnetic resonance angiography.
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Reovirus type III infection causes mild rhinitis and pharyn-
gitis and upper respiratory tract infections are frequently 
observed before the onset of CS.6
Immunological mechanisms play a role in CS pathogen-
esis; Hughes et al28 reported that serum antibodies to unde-
fined corneal antigens and to a mixture of inner ear extracts 
could initiate or perpetuate the immune response in patients 
with the disease. Antibodies against a peptide antigen (Cogan 
peptide) have been found in sera from patients with CS. This 
peptide antigen shares sequence homology with CD148 and 
Connexin 26, which are expressed on endothelial cells and 
in the inner ear.29 Antibodies directed against the Cogan 
peptide showing similarities with auto-antigens, including 
CD148, were identified. The same antibodies also are bound 
to Connexin 26, which has been implicated in congenital 
deafness; furthermore, the loss of this protein results in 
potassium-mediated damage to the organ of Corti, leading 
to hearing loss. Connexin 26 shows similarity to Connexin 
43 and Connexin 50, gap junction proteins present in corneal 
fibroblasts and epithelium.30 Since nonsyphilitic IK is another 
key feature of CS, this homology might have implications in 
explaining the eye involvement in the disease. The antigen 
is also expressed on nerve and glial cells and may explain 
the wide clinical spectrum of CS, including the neurological 
abnormalities.31
The induction of clinical features of CS in animals after 
either passive transfer of peptide-specific autoantibodies or 
active immunization with autoantigen peptides suggests that 
CS may be have an autoimmune basis. After passive transfer 
of antibodies directed against the Cogan peptide into Balb/c 
mice, antibodies were found within the cochlea of the tested 
animals, whereas antibodies against an irrelevant peptide did 
not bind to cochlear cells,29 six of six Balb/c mice injected 
with the purified antibodies developed hearing loss found 
via the recording of auditory brainstem responses in mice, 
showing that an higher stimulus intensity was necessary to 
obtain smaller and more delayed responses after immuniza-
tion compared to pretreatment. Also, Lunardi et al29 showed 
that a rabbit immunized with different peptides derived from 
CD148 developed hearing loss and IK.
Diagnosis
The diagnosis of CS is mainly clinical and is based on 
audio-vestibular symptoms, ocular inflammation, and non-
reactive serological tests for syphilis.32 Diagnosis requires a 
 multidisciplinary approach, as also reported in other similar 
autoimmune conditions involving the auditory system.33–35 
The variable onset of symptoms and the lack of specific labo-
ratory tests contribute to challenges in making CS diagnosis 
that is often based on the good response to corticosteroid 
treatment.9,36 Clinical diagnostic criteria of CS include man-
datory, prevalent, and possible additional criteria. Mandatory 
criteria include sensorineural hearing loss, inflammatory 
ocular disease, and the exclusion of alternative causes of 
inflammation or infection. Prevalent additional criteria 
include vertigo, tinnitus, ataxia, dizziness, fever, weight loss, 
fatigue, lymphadenopathy, and headache. Possible additional 
criteria include large or – rarely – medium and small ves-
sel vasculitis and positivity to laboratory tests for systemic 
inflammatory markers (Table 1). Globally diagnostic criteria 
for CS are still missing.
Laboratory tests commonly used to detect autoimmune 
diseases are rarely positive in CS; a negative result does 
not rule out CS. No specific laboratory tests are diagnostic 
for CS, although the erythrocyte sedimentation rate is often 
elevate during active disease.9 Multiple studies indicated 
various antibodies directed against inner ear, corneal, and 
endothelial antigens as possible serological markers of the 
disease.15,16 In particular, antibodies against Cogan peptide, 
an antigen that shares sequence homology with CD148 and 
Connexin 26, were investigated.29 Moreover, identification of 
antibodies anti-heat shock protein 70 (Hsp70) was identified 
in patients with sensorineural hearing loss; assaying these 
antibodies in serum could represent a serological marker for 
CS.37 Some studies evaluated the rate of CS patients positive 
for anti-Hsp70 ranging from 45% to 50%.38,39 A prevalence of 
positive anti-Hsp70 was observed in patients affected by typi-
cal CS compared to those with atypical CS (66.7% vs 37.5%, 
respectively).39 Thus, prevalence of anti-Hsp70 in typical CS 
was also significant compared to patient affected from autoim-
mune sensorineural hearing loss and controls. In the pediatric 
Table 1 Criteria for clinical diagnosis of Cogan’s syndrome
Mandatory criteria Prevalent additional criteria Possible additional criteria
Sensorineural hearing loss Vertigo, dizziness, ataxia Vasculitis
Inflammatory ocular disease Tinnitus Positivity for systemic inflammatory markers
Alternative causes of inflammation or 
infection ruled out
Nonspecific systemic symptoms such as weight loss, 
fever, lymphadenopathy, and headache
Note: Mandatory and on prevalent and possible additional criteria for clinical diagnosis of Cogan’s syndrome.
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age, typical CS may develop with negative anti-Hsp70. This 
clinical behavior may be explained with the uncompleted 
development of “immunity competence”, as proposed by 
some authors.40 In these cases, test repetition is recommended 
after the age of complete immune competence.38
Other authors suggested the association of CS and 
antineutrophil cytoplasmic antibodies (ANCA).41 ANCA 
have recently been identified in patients with systemic vas-
culitis, such as Wegener’s granulomatosis, Churg-Strauss 
syndrome, and polyarteritis nodosa. After the discovery of 
ANCA, myeloperoxidase (MPO) and proteinase 3 (PR3) 
were identified as the two major antigens.42 Normally, 
MPO and PR3 are localized intracellularly; however, when 
neutrophils are preactivated by proinflammatory cytokines, 
these enzymes become expressed on the cell surface and 
are accessible to circulating ANCA. These antibodies may 
be involved in the immune pathogenesis of vasculitis by 
the activation of primed neutrophils, leading to the release 
of lytic enzymes.43,44 Tervaert et al reported one case of CS 
that was also positive for MPO ANCA and anti-human leu-
kocyte elastase ANCA.45 Yamanishi et al described a case of 
atypical CS associated with ANCA.41 To date, five cases of 
CS associated with ANCA have been reported41 and two of 
them also showed ANCA-related glomerulonephritis. Previ-
ously, Cheson et al8 reviewed 53 cases of CS; 10/18 vessel 
or muscle biopsy specimens showed inflammatory vascular 
changes, of which four were considered to be diagnostic of 
polyarteritis in large- and medium-sized arteries. A com-
mon pathological feature of ANCA-associated vasculitis is 
necrotizing vasculitis of small vessels;46 therefore, arteries 
of all sizes may be affected in CS.
Radiographic studies, such as cranial computed tomogra-
phy (CT) and magnetic resonance imaging (MRI), are often 
normal in CS patients.9 Some authors have reported the pres-
ence of labyrinthine aspecific radiological abnormalities in 
MRI scans with gadolinium contrast like calcification or nar-
rowing and soft tissue obliteration of the vestibular labyrinth 
and the cochlea.36 Positron emission tomography (PET) with 
2-deoxy-2-[18F]fluoro-d-glucose (FDG-PET/CT) scanning 
has been reported as an additional diagnostic examination to 
assess involvement in large vessel vasculitis common in CS. 
In a case report, Balink et al supported the hypothesis that 
with PET, the inflammatory activity of large-vessel vasculitis 
could be more accurately assessed compared to laboratory 
acute-phase parameters (Figure 2).47,48
Differential diagnoses to consider are Takayasu’s 
 arteritis,49,50 polyarteritis nodosa, Wegener’s granulomatosis, 
giant cell arteritis, and rheumatic arthritis.6 It is particularly 
difficult to distinguish between Takayasu’s arteritis and the 
Figure 2 Aortitis in Cogan’s syndrome.
Notes: (A) Transverse hybrid PET/CT slice; pathological uptake in the wall of the 
aortic arch, more intense in the lateral wall and perivascular space adjacent to the 
truncus pulmonalis. (B) Follow-up PET/CT showed clearly decreased uptake in 
the aortic arch after 3 weeks treatment with methyl-prednisolon intravenous and 
prednisolon orally. (C) Second follow-up PET/CT 6 months later (patient was in 
a stable condition with methotrexate and low-dose prednisone) with again high 
uptake in the wall of the aortic arch, with higher intensity in the lateral wall and 
perivascular space adjacent to the truncus pulmonalis. Methotrexate and prednisone 
were increased to 20 mg/day.  Reproduced from Balink H, Bennink RJ, van Eck-
Smit BL, Verberne HJ. The role of 18F-FDG PET/CT in large-vessel vasculitis: 
appropriateness of current classification criteria? Biomed Res Int. 2014;2014:687608). 
Copyright © 2014 H. Balink et al. Creative Commons License available at: https://
creativecommons.org/licenses/by/3.0/.48
Abbreviations: CT, computed tomography; PET, positron emission tomography.
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vasculitis of CS because they both involve medium and – 
mainly – large vessels. However, unlike CS, Takayasu’s 
arteritis does not involve the eyes.49,51 Rheumatoid factor, 
anti-nuclear, and anti-endothelial antibodies have also been 
reported in some patients with CS, further supporting the 
autoimmune origin theory.3
Multidisciplinary approach to 
treatment of CS
CS is a systemic disease that can lead to severe functional 
impairments; therefore, clinical management and treatment 
must involve by different specialists whose competencies 
should be coordinated.52 Preclinical therapeutic management 
in patients with CS is not considered in clinical practice since 
CS is often diagnosed following clinical manifestations.
Clinical diagnosis of CS is based on the following three 
mandatory criteria: sensorineural hearing loss, inflamma-
tory ocular disease, and alternative causes of inflammation 
or infection ruled out. Prevalent additional criteria include 
vertigo, tinnitus, ataxia, dizziness, fever, weight loss, fatigue, 
lymphadenopathy, and headache. Among possible additional 
criteria, it is important to consider large or – rarely – medium 
and small vessel vasculitis and positivity to laboratory tests 
for systemic inflammatory markers (Table 1). Treatment of 
the CS depends on its severity and organ involvement.3,53 In 
cases with mild eye involvement, the treatment of choice is 
the application of topical glucocorticoids and cycloplegic 
agents, such as atropine eye drops. In a case report, topical 
cyclosporine A (CyA) was used successfully in the treat-
ment of severe anterior segment inflammation.54 Patients 
with posterior involvement (retinal vasculitis and posterior 
uveitis) often require systemic treatment.
The involvement of the inner ear, a severe inflammation 
of the eye, and the development of systemic vasculitis require 
systemic immunosuppressive therapy. Corticosteroids at high 
dosages remain the mainstay at the beginning and during the 
acute phases of the disease.52
Pharmacological treatment
Corticosteroids
Though reported to be the standard of care and of promising 
outcome, there are no double blind controlled studies to show 
the beneficial effects of corticosteroids in CS management 
and treatment.6,7,55 A clinical response to steroids may also 
help a challenging diagnosis as an “ex juvantibus” criterion. 
In these cases, systemic corticosteroids are considered as the 
primary standard of care for CS. In response to corticosteroid 
therapy, the ocular symptoms have been reported to be more 
responsive than the audio-vestibulary symptoms and a poor 
clinical response to this therapy may indicate a possible 
misdiagnosis rather than a resistant form.52
In early stages of the disease, a limited vasculitis results 
in labyrinthine ischemia, with a beneficial response to steroid 
treatment. Over the long term, the organ of Corti can degen-
erate, with the development of fibrosis and osteoneogenesis 
within the perilymphatic space; in such cases, significant 
improvement should not be expected.10
At the onset of audio-vestibular dysfunction, rapid initia-
tion of high dose corticosteroids (1–1.5 mg/kg of prednisone 
daily) is recommended, expecting a beneficial response to 
be noticed within 2–3 weeks.7,56 Cabezas-Rodriguez et al57 
reported significant hearing improvements after treatment 
with intravenous methylprednisolone. This single-drug regi-
men, however, should last no longer than 2–3 weeks due to 
either the development of significant glucocorticoid-induced 
toxicity or the inability to taper the dosage maintaining the 
control of the disease.52 When hearing improves, based on the 
responses of pure tone audiometry, steroids should be tapered 
slowly and usually continued for 2–6 months.52
The importance of corticosteroid therapy was confirmed 
in a 5-year follow-up study conducted by Haynes in which 
95% of untreated patients with CS developed permanent 
hearing loss compared to only 55% of patients treated with 
systemic steroids within 2 weeks of initial hearing loss.7 
Nevertheless, some authors have noted that although hearing 
loss progression could be slowed with corticosteroid treat-
ment, bilateral audio-vestibular dysfunction in CS could not 
be prevented.58,59
The vasculitis and other prominent systemic complica-
tions of CS usually respond well to systemic corticosteroids, 
which have proven to be of short-term benefit; however, they 
can also be associated with side effects. Short-term corti-
costeroid use is associated with generally mild side effects, 
including cutaneous effects, electrolyte abnormalities, 
hypertension, hyperglycemia, pancreatitis, hematological, 
immunological, and neuropsychological effects. Long-term 
corticosteroid use may be associated with more serious 
sequela, including osteoporosis, aseptic joint necrosis, 
adrenal insufficiency, gastrointestinal, hepatic, and ophthal-
mological effects, hyperlipidemia, and growth suppression.
Since high doses of corticosteroids or prolonged treat-
ment courses were required in many CS patients, other immu-
nosuppressive agents such as cyclophosphamide (Cyc),60 
azathioprine (AZA), methotrexate (MTX),61 CyA and tumor 
necrosis factor alpha (TNFα) blockers were often combined 
to steroids.43,44 Specifically, infliximab (IFX) appears to be 
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effective when initiated at an early stage of inner ear disease 
and afterward in maintaining remission in patients with 
therapy-resistant CS.62
Cyclophosphamide
Cyc is an alkylating agent usually used for the treatment of 
severe uveitis/scleritis and systemic vasculitis. Cyc is an inac-
tive drug that is converted into phosphoramide mustard and 
acrolein by the cytochrome P-450 oxidase system in the liver; 
the active form is able to introduce alkyl radicals into DNA 
strands. One retrospective multicentric study reported the use 
in CS as well as in some case series.60,63 The majority of the 
described patients receiving pulse intravenous Cyc combined 
with oral glucocorticoids with a clinical stabilization of CS. 
Nevertheless, some articles described only a partial or short-
term response,46,59,60,64,65 or a lack of response;12,15,60,66,67 in 
some cases, discontinuation was warranted due to systemic 
side effects.60,63
Methotrexate
MTX is an inhibitor of the dihydrofolate reductase, essential 
for DNA replication, that interferes with the synthesis of 
purine nucleotides and thymidylate. MTX can be consid-
ered a second-line, steroid-sparing therapy for CS. Two 
small-sized prospective studies evaluate the use of MTX 
for refractory autoimmune inner ear disease. In both stud-
ies, the cohort included three CS patients with a clinical 
improvement of the disease.68,69 Thus, the efficacy and safety 
of MTX was assessed in several case series, case reports 
and one retrospective study, mainly during the maintenance 
phase.12,32,44,51,61,64,70,71 The use of MTX was discussed as 
an option also for the treatment of CS in pediatric age.72,73 
Intolerance or poor effectiveness of this immunosuppressant 
in CD has been reported.12,15,43,70,74
Azathioprine
AZA is a prodrug that is metabolized by the liver to its active 
form. It interferes with DNA, RNA, and protein syntheses. 
It inhibits maturation of B and T lymphocytes, interfering 
with immunoglobulin M  production and interleukin (IL)-2 
synthesis. The use of AZA is reported only in several reports 
in CS, and efficacy and tolerability were variable.59,60,62,67,75,76 
The efficacy of the sole AZA in the maintenance phase was 
reported only in three cases.77–79
Cyclosporine A
CyA is a cyclic peptide, which binds to cyclophilin of T lym-
phocytes; thus, CyA is able to reduce the release of several 
cytokines. The use of CyA combined with corticosteroid 
and other immunosuppressive agents in CS was documented 
in some case reports,59,63,65,76,80 two case series,60,64 and one 
prospective nonrandomized clinical study including four 
patients with typical CS.81 The efficacy was variable with 
good response for ocular manifestations, quite effective for 
possible systemic vascular involvement but less effective for 
the audio-vestibular symptoms.
Biological therapy
Biological therapy for the treatment of autoimmune diseases 
consists of genetically engineered proteins derived from 
human genes. These proteins are designed to inhibit specific 
components of the immune system that play essential roles 
in driving the inflammatory pathway involved in the differ-
ent diseases.52 The use of biological therapy in CS patients 
included for anti-TNFα agents, rituximab (RTX) and tocili-
zumab (TCZ).
Anti-TNFα
Anti-TNFα has been introduced in early 2000s. TNFα is a 
cytokine released during infection and inflammation. TNFα 
can induce pleiotropic effects, as pyrogenic activity when 
affecting the hypothalamus, production of C-reactive protein, 
and other acute-phase reactants by the liver. It is a potent 
chemoattractant for innate immune cells and promotes the 
expression of adhesion molecules by endothelial cells.82 
TNFα inhibition causes a decrease in interferon-γ and an 
increase in IL-4 produced by T cells, inducing a shift of the 
immune response, with a reduction of clinical disease activity. 
TNFα is also a balancing factor required for the reestablish-
ment of physiological homeostasis and immune regulation.52
Currently available anti-TNFα agents for clinical use 
are one soluble TNFα receptor (etanercept [ET]) and four 
anti-TNFα monoclonal antibodies, such as IFX, adalimumab 
(ADA), golimumab, and certolizumab pegol. In some cases, 
the lack of efficacy of anti-TNFα monoclonal antibodies is 
due to the production of serum antidrug antibodies. Concomi-
tant use of anti-TNFα with traditional immunosuppressive 
drugs such as MTX and AZA may prevent the produc-
tion of serum antidrug antibodies. Thus, TNFα antibodies 
themselves may trigger neurological symptoms, which may 
include CS-like symptoms, as shown in cases treated with 
anti-TNFα for inflammatory diseases.83,84
Infliximab
IFX is a chimeric monoclonal IgG1 antibody that specifi-
cally binds to both soluble and membrane-bound TNFα with 
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high affinity, forming stable nondisassociating immune 
complexes. This activity prevents the binding of TNFα to 
its receptors and blocks the initiation of the intracellular 
signaling that leads to gene transcription and subsequent 
biological inflammatory activity.52 Regretfully, there are lim-
ited data in the literature that does not allow drawing reliable 
conclusions. Only 12 cases of CS are reported in the litera-
ture, treated with intravenous infusion of IFX, previously 
treated with corticosteroid and other immunosuppressive 
drugs with poor benefits.43,62,70,82,85 The used dosage ranged 
between 3 mg/kg and 400 mg total. In a pediatric patient with 
tubulointerstitial nephritis and uveitis (TINU) syndrome, 
transtympanic dexamethasone injections and IFX infusions 
were initiated at the onset of dizziness and severe bilateral 
sensorineural hearing loss, with a diagnosis of atypical CS in 
addition to the TINU syndrome. The IFX treatment was suc-
cessful except in one case, allowing corticosteroid tapering 
and an improvement of hearing and/or ocular disease. In six 
cases, IFX treatment was successful after the failure of Cyc. 
In one unsuccessful case, IFX was administered 30 months 
after the diagnosis of CS.
Etanercept
ET is a fusion protein consisting of two recombinant p75 
TNFα receptors linked to the Fc portion of human IgG186 that 
is a powerful antagonist of TNF, binding to and inactivating 
this cytokine. ET is approved for the treatment of several 
autoimmune diseases, such as rheumatoid arthritis, anky-
losing spondylitis, juvenile rheumatoid arthritis, psoriasis, 
and psoriatic arthritis. However, in contrast to anti-TNFα 
antibodies, it is less effective in inflammatory bowel disease 
and in autoimmunity of the eye (eg, uveitis).82 The efficacy 
of the ET was examined in a prospective study including 
patients with bilateral immune-mediated audio-vestibular 
disorders; of these, three patients with CS were present.87 In 
two patients, an improvement was assessed, although ET did 
not succeed in preventing hearing loss.
Adalimumab
ADA is a human recombinant monoclonal IgG1 antibody 
with high specificity for human TNFα, thus inhibiting the 
TNFα binding to surface cellular receptors p55 and p75. 
Subcutaneous injections of ADA were documented in two 
cases of multidrug-resistant CS. In one case of typical CS, a 
dose of 40 mg/week for 6 months associated with prednisone 
and MTX failed in preventing a worsening of hearing loss.88 
In another case, a patient with atypical CS experienced a clini-
cal worsening during treatment.76 However, efficacy of this 
drug was assessed in cases of systemic autoimmune diseases 
associated with sensorineural hearing loss.89–91
Tocilizumab
TCZ is a recombinant humanized monoclonal anti-IL-6 
receptor antibody that inhibits both membrane-bound and 
soluble IL-6 receptors. TCZ action inhibits T-cell activation 
and antibody secretion and decreases circulating cells from 
myeloid lineage. Only two case reports show the use of TCZ 
in CS.76,92 In one case of long-standing resistant atypical CS, 
TCZ (8 mg/kg intravenously/month) successfully replaced 
ADA stabilizing the course of the disease.76 In the second 
case, the use of TCZ was associated with pulmonary toxicity.92
Rituximab
RTX is a chimeric murine-human monoclonal IgG1 antibody 
directed against lymphocyte CD20 surface antigen, inducing 
a depletion of B lymphocytes by various mechanisms. This 
activity is associated with antibody-dependent cell-mediated 
cytotoxicity and complement-dependent cytotoxicity, 
although direct growth inhibition and/or induction of apop-
tosis may also take place. In a case report from Orsoni et al,88 
RTX was used in a patient with a multidrug-resistant form of 
typical CS. In this case, RTX was administered, associated 
with oral prednisone, at a dosage of 500 mg intravenous/
week. A noticeable improvement in hearing was reported. A 
poor response was reported in a patient with atypical CS and a 
remitting non-Hodgkin lymphoma of the mastoid bone.85 The 
recommended dose of the drug is the 4-week division of the 
overall cycle dose as it appears to be particularly safe, even 
though its use as a first-line therapy is not recommended.88
Surgical treatment
As for other autoimmune syndromes, surgery should be post-
poned until a long-term medical control of the inflammatory 
manifestations is obtained. In cases with severe sensorineural 
hearing loss unresponsive to intensive and/or innovative 
immunosuppressive regimens, cochlear implantation is still a 
valuable rescue surgical strategy for functional maintenance.
Generally, postoperative hearing outcome has been 
reported to be good to excellent; stable postoperative hear-
ing has been reported at follow-up after 1,93 2,94 and 5 years95 
with good-to-excellent word and sentence discrimination 
scores. These results suggest that cochlear implantation may 
provide excellent and stable hearing rehabilitation in long-
term follow-up in most patients with CS.
Partial obliteration or neo-ossification of the cochlea was 
encountered during cochlear implantation, which required an 
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alteration of the standard surgical technique.96 A preoperative 
MRI scan is necessary to identify patients with obliteration 
or neo-ossification of the cochlea and predict the difficulty 
encountered during insertion of the implant electrode.
Fibrous obliteration of the scala tympani was found as 
early as 8 weeks after onset of deafness.96 Generally, new 
bone formation is seen in the cochlea after cochlear implan-
tation for the deafness of various etiologies as well as in the 
cochleae deafened by the CS without cochlear implantation. 
Postoperative word discrimination scores have been reported 
to be negatively correlated with the percent volume of new 
bone formation within the cochlea after implantation.97
Deterioration of auditory performance after cochlear 
implantation has been described in two cases,98 presumably 
secondary to an ongoing inflammatory response due to CS 
pathogenic basis. In one case, deterioration in speech percep-
tion was attributed to progressive cochlear ossification. In the 
other case, an abrupt deterioration of loudness perception 
required an increase in electrical stimulation.
Conclusion
CS is a rare disorder characterized by nonsyphilitic IK and 
audio-vestibular symptoms. Typical CS manifests primar-
ily with IK and hearing loss, whereas atypical CS usually 
presents with inflammatory ocular manifestations and, more 
frequently, with systemic inflammation (70%), of which 
vasculitis represents the main pathogenic mechanism.
CS is considered as an autoimmune- or immune-mediated 
disease supported mainly by the beneficial response to cor-
ticosteroids. Antibodies to inner ear antigens, anti-Hsp70, 
and ANCA were associated with CS. Treatment of CS is 
sometimes difficult and frustrating. Failure to treat hearing 
loss may lead to deafness, and repeated flares may lead to 
profound and permanent hearing loss despite initial control 
of hearing damage.
Corticosteroids are the first line of treatment; multiple 
immunosuppressive drugs have been tried with variable 
degrees of success. TNFα blockers and other biological 
drugs have added promising options to the management of 
severe manifestations and/or recalcitrant forms, although 
refractory cases are still reported, most concerning the 
hearing function. The use of these molecules also in the 
early stages of the disease should be considered in order to 
exploit their potentialities even in cases that are not definitely 
compromised. At present, the concomitant use of anti-TNFα 
and traditional immunosuppressive drugs, such as MTX and 
AZA, is considered as the preferred option. Future directions 
of research for CS should consider prospective randomized 
trials that compare the efficacy and the safety profile of dif-
ferent therapeutic regimens in order to optimize the approach 
to such a rare and kaleidoscopic disease.
Cochlear implantation is a valuable rescue surgical strat-
egy in cases with severe sensorineural hearing loss unrespon-
sive to intensive and innovative immunosuppressive regimens.
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